NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the...
- Sep 21
Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round
Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants NORTH BRUNSWICK, N.J., Sept. ...
- Sep 7
Precision Livestock Technologies Closes Preferred Equity Financing
Capital to Support Commercialization and Ongoing R&D Engages Checkmate Capital Group as Strategic Advisor PASADENA, Calif. and DALLAS,...
- Jun 27
Checkmate Capital Group and KAIST Venture Investment Holdings Announce Partnership
Checkmate Capital Group and KAIST Venture Investment Holdings Announce Partnership & Selection as TIPS Operator LOS ANGELES and SEOUL,...
- Jun 23
Elucid Raises $27 Million Series B Funding Round
Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis BOSTON, June 22, 2022...
- Jun 20
KT Corporation and Hanmi Pharmaceutical promote business cooperation with Digital Pharm
KT Corporation and Hanmi Pharmaceutical promote business cooperation with Digital Pharm, a Korean company specializing in digital...
- Jun 14
UCLA Researchers Receive NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide...
- Apr 7
NeuroSigma Announces MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to...